drugset
drugset / Trial / NCT00690443

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

NCT00690443 ↗

Phase 2 Completed 44 enrolled Aegerion Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.

Timeline

Start
2008-05
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 20 mg —
Comparator lomitapide Small molecule 5 mg —

Indications

hyperlipidemia